MX2019010107A - Composicion para administracion intravesical para tratar el dolor en la vejiga. - Google Patents

Composicion para administracion intravesical para tratar el dolor en la vejiga.

Info

Publication number
MX2019010107A
MX2019010107A MX2019010107A MX2019010107A MX2019010107A MX 2019010107 A MX2019010107 A MX 2019010107A MX 2019010107 A MX2019010107 A MX 2019010107A MX 2019010107 A MX2019010107 A MX 2019010107A MX 2019010107 A MX2019010107 A MX 2019010107A
Authority
MX
Mexico
Prior art keywords
composition
bladder pain
intravesical administration
treating bladder
administration
Prior art date
Application number
MX2019010107A
Other languages
English (en)
Inventor
Van Hemelrijck Carlos
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2019010107A publication Critical patent/MX2019010107A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se relaciona con una composición farmacéutica que comprende cis-(E)-4-(3-fluorofenil)-2',3',4',9'-tetrahidro-N,N-dim etil-2'-(1-oxo-3-fenil-2-propenil)-spiro[ciclohexano-1,1'[1H]-pir ido[3,4-b]indol]-4-amina. La composición farmacéutica es adecuada para la administración tópica, especialmente para administración intravesical en el tratamiento de dolor en la vejiga.
MX2019010107A 2017-02-24 2018-02-23 Composicion para administracion intravesical para tratar el dolor en la vejiga. MX2019010107A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17020068 2017-02-24
PCT/EP2018/054453 WO2018154028A1 (en) 2017-02-24 2018-02-23 Composition for intravesical administration for treating bladder pain

Publications (1)

Publication Number Publication Date
MX2019010107A true MX2019010107A (es) 2019-11-21

Family

ID=58231332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010107A MX2019010107A (es) 2017-02-24 2018-02-23 Composicion para administracion intravesical para tratar el dolor en la vejiga.

Country Status (11)

Country Link
US (1) US20180243273A1 (es)
EP (1) EP3585359A1 (es)
JP (1) JP2020508332A (es)
CN (1) CN110494128A (es)
AU (1) AU2018223906A1 (es)
BR (1) BR112019016545A2 (es)
CA (1) CA3054374A1 (es)
EA (1) EA201991960A1 (es)
MX (1) MX2019010107A (es)
TW (1) TW201832765A (es)
WO (1) WO2018154028A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020030777A1 (en) * 2018-08-10 2020-02-13 Grünenthal GmbH Composition for treating urinary frequency and/or urinary urgency

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
MX360290B (es) * 2013-03-15 2018-10-29 Gruenenthal Gmbh Cis-(e)-4-(3-fluorofenil)-2',3',4,9'-tetrahidro-n,n-dimetil-2'-(1 -oxo-3-fenil-2-propenil)-espiro[ciclohexan-1,1'[1h]-pirido[3,4-b] indol]-4-amina cristalina.

Also Published As

Publication number Publication date
EA201991960A1 (ru) 2020-01-24
TW201832765A (zh) 2018-09-16
US20180243273A1 (en) 2018-08-30
CA3054374A1 (en) 2018-08-30
WO2018154028A1 (en) 2018-08-30
BR112019016545A2 (pt) 2020-03-31
CN110494128A (zh) 2019-11-22
EP3585359A1 (en) 2020-01-01
AU2018223906A1 (en) 2019-10-17
JP2020508332A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
TN2020000001A1 (en) Carboxamides as modulators of sodium channels
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
MY188139A (en) Sodium channel modulators for the treatment of pain
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
TN2014000326A1 (en) Inhibitors of beta-secretase
MX2021002321A (es) Nuevos metodos.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
CL2008002747A1 (es) Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros.
MX356343B (es) Compuestos que inhiben la exocitosis neuronal (ii).
JOP20200073A1 (ar) مركبات أميد إيميدازوبيريدين تحمل بدائل واستخداماتها
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2018007152A (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MD20150030A2 (ro) Inhibitori de beta-secretază
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
MX2020006174A (es) Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas.
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX363200B (es) Composición odontológica de papaína en gel para el tratamiento atraumático de caries y método para prepararla.
EA202190281A1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана
CA3010788A1 (en) Methods of administering vasopressors
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders